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Polymyxin antibiotics are considered a last line of defense in thetreatment of severe infections caused by multidrug-resistant
and extensively drug-resistant Gram-negative pathogens. How-
ever, the recent discovery of the plasmid-mediated polymyxin an-
tibiotic resistance gene mcr-1 and its apparent diffusion into en-
vironmental, food animal, and retail food sources and clinical
settings threaten to stem the clinical utility of polymyxin antibiot-
ics (1–5). The mcr-1 gene encodes a phosphoethanolamine trans-
ferase which modiﬁes lipid A in the outer membranes of Entero-
bacteriaceae, leading to decreased binding afﬁnities of polymyxin
antibiotics (1, 6).
Since there exists the possibility that modiﬁcation of the outer
membrane of Gram-negative bacteria has amore general effect on
antibiotic susceptibility, the in vitro activity of the novel ﬂuorocy-
cline antibiotic eravacycline was evaluated against a diverse set of
mcr-1-positiveEscherichia coli clinical (n 16) and animal (n 1)
isolates, Salmonella enterica animal isolates (n 4), and a set of 4
carbapenem-resistant clinical isolates comprised of E. coli, Entero-
bacter cloacae, and Klebsiella pneumoniae engineered to overex-
press the mcr-1 gene.
Susceptibility to eravacycline and comparators was evaluated
by broth microdilution MIC assays performed according to Clin-
ical and Laboratory Standards Institute (CLSI) methodology (7).
Antibiotics were obtained from Sigma-Aldrich (St. Louis, MO).
The set of 21 nonclonal strains tested, carrying the mcr-1 gene either
chromosomally or on one of four different plasmids, was collected
from sources in Switzerland (n  5), South Africa (n  7), France
(n  3), Portugal (n  4), and the Centers for Disease Control
(CDC0346, CDC349 [http://www.cdc.gov/drugresistance/resistance
-bank/currently-available.html];n2) and included representatives
from at least 14 sequence types. The presence of the mcr-1 gene was
conﬁrmed using published PCR primers and methods (1). The
eravacycline MIC50 andMIC90 values against this panel were 0.25
and 0.5g/ml, respectively, similar to values for the in-class com-
parator tigecycline (Table 1). Nine isolates were resistant to 3rd-
and/or 4th-generation cephalosporins, and 19 were resistant to
tetracycline. The MIC50 and MIC90 values for colistin were 8 and
16 g/ml, respectively, and those for polymyxin B were 4 and 8
g/ml, respectively; 20/21 isolates showed MIC values of 4
g/ml for colistin and/or polymyxin B.
To evaluate the speciﬁc effects of mcr-1 expression in the ab-
sence of other resistance determinants that may be present in nat-
urally occurringmcr-1-positive clinical isolates (8), themcr-1 gene
was PCR ampliﬁed from mcr-1-positive isolate Af23 (9) using the
forward and reverse primers GCGCGGTCATGATGCAGCATAC
TTCTGTGTG and GCGGCCTCGAGTCAGCGGATGAATGCG
GTG,with additions of 5=BspHI and 3=XhoI cloning sites, respec-
tively. Themcr-1 sequence was conﬁrmed to be identical to that of
GenBank accession number KX032519. The mcr-1 gene was
cloned into the NcoI and XhoI cloning sites of the pBADB-genta-
micin vector under the control of an arabinose-inducible pro-
moter, similar to what has previously been reported (6). The
pBADB-gentamicin vector was constructed by cloning the
acc(3)-I aminoglycoside 3-N-acetyltransferase gene from plas-
mid pUCGM (GenBank accession number U04610) into the
pBADB vector (Thermo Scientiﬁc,Waltham,MA) using KpnI and
XbaI sites downstream of the multiple cloning site. A plasmid
bearing the E. coli lacZ gene was cloned into the same expression
vector and used as a negative control. Plasmids were transformed
into the polymyxin-sensitive E. coli laboratory strain DH10B
(Thermo Fisher Scientiﬁc, Waltham, MA) and into clinical iso-
lates of E. coli (CDC0150 blaNDM-5), K. pneumoniae [CDC0146
blaNDM tet(A) and CDC0160 blaOXA-48], and E. cloacae [CDC0050
blaKPC tet(A)] from the carbapenemase detection and diversity
panels available from the CDC (http://www.cdc.gov
/drugresistance/resistance-bank/currently-available.html). Plasmid-
containing strains were maintained in 5 g/ml gentamicin and
induced for 30 min at room temperature with 1% D-arabinose
prior to the assay. MIC assays were conducted according to CLSI
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TABLE 1 Activities of eravacycline against mcr-1-positive E. coli and S.
enterica isolatesa
Antibiotic MIC50, MIC90 (g/ml) Range (g/ml) % susceptible
Eravacycline 0.25, 0.5 0.031 to 0.5 NA
Colistin 8, 16 1 to 16 NA
Polymyxin B 4, 8 0.5 to 8 NA
Tetracycline 32,32 0.5 to32 9.5
Tigecycline 0.25, 0.5 0.063 to 1 100
Gentamicin 2,32 0.5 to32 71.4
Aztreonam 0.25,32 0.063 to32 57.1
Meropenem 0.031, 0.063 0.016 to 0.063 100
Cefepime 1,32 0.13 to32 57.1
Ceftazidime 0.5,32 0.25 to32 66.7
Cefotaxime 0.25,32 0.063 to32 57.1
Levoﬂoxacin 8,32 0.063 to32 42.8
a MIC50 and MIC90 values were determined by broth microdilution MIC assays,
performed in duplicate (at least) for each isolate, and representative data are shown.
Data shown are for a total of 21 isolates. NA, not available. % susceptible, percentage of
susceptible isolates according to CLSI (10) or FDA (for tigecycline) (11) guidelines.
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methodology, with the exception that both gentamicin and arabi-
nose were present. Results showed that while overexpression of
mcr-1 in each clinical isolate raised theMIC values for colistin and
polymyxinBby 32- to 64-fold, therewas no effect on susceptibility
to eravacycline and other comparators (i.e., MIC values with and
without mcr-1 overexpression were within 2-fold of those of the
lacZ control strain) (Table 2). It was noted that the MIC values of
the cell wall-inhibiting antibiotics meropenem, cefepime, ceftazi-
dime, and cefotaxime for plasmid-containing strains (expressing
either lacZ or mcr-1) generally were lower (when endpoints were
available) than those for the corresponding “no-plasmid” con-
trols. Since similar MIC values were obtained for strains express-
ing either lacZ ormcr-1, the lowerMIC valuesmay be attributed to
general effects on growth rate due to recombinant expression or
antibiotic interactions due to the presence of gentamicin in assays
with the plasmid-containing strains.
In conclusion, the present study showed that eravacycline was
potent in vitro against naturally occurringmcr-1-positive bacterial
isolates and unaffected by the overexpression of mcr-1 in Entero-
bacteriaceae.
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TABLE 2 Activities of eravacycline and comparators against carbapenem-resistant E. coli, K. pneumoniae, and E. cloacae clinical isolates
recombinantly expressing mcr-1
Antibiotic
MIC (g/ml) of the following strain with the indicated characteristic:
E. coli
DH10B
E. coli
CDC0150 blaNDM-5
K. pneumoniae
CDC0146 blaNDM tet(A)
K. pneumoniae
CDC0160 blaOXA-48
E. cloacae
CDC0050 blaKPC tet(A)
lacZ mcr-1 No plasmid lacZ mcr-1 No plasmid lacZ mcr-1 No plasmid lacZ mcr-1 No plasmid lacZ mcr-1
Eravacycline 0.13 0.13 0.13 0.063 0.13 0.5 1 0.5 0.25 0.25 0.5 0.5 0.25 0.25
Colistin 0.063 4 0.25 0.13 8 0.25 0.13 8 0.5 0.25 8 0.13 0.13 8
Polymyxin B 0.063 4 0.25 0.063 4 0.13 0.13 8 0.25 0.13 8 0.13 0.13 4
Tetracycline 2 2 32 32 32 32 32 32 8 4 4 4 2 2
Tigecycline 0.13 0.13 0.25 0.25 0.5 1 2 1 0.5 0.5 0.5 0.5 0.5 0.5
Aztreonam 0.25 0.13 32 32 32 32 32 32 0.25 0.25 0.13 32 32 32
Meropenem 0.031 0.031 32 16 16 32 8 4 32 8 8 1 0.25 0.25
Cefepime 1 0.5 32 32 32 32 32 32 8 4 2 32 8 16
Ceftazidime 0.5 0.5 32 32 32 32 32 32 1 0.5 0.5 32 32 32
Cefotaxime 0.063 0.063 32 32 32 32 32 32 8 2 1 32 4 8
Levoﬂoxacin 0.016 0.016 32 32 32 32 32 32 0.063 0.063 0.063 16 8 8
MIC values were determined by broth microdilution MIC assays, performed in duplicate (at least) for each isolate according to CLSI standard procedures, with the exception that
gentamicin at 5 g/ml and 1% D-arabinose were present in assays with plasmid-containing strains. Representative results are shown.
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